AC Immune

AC Immune

Yahoo Finance • 8 days ago

Vertex Posts Positive Phase II Data on Kidney Disease Drug

Vertex Pharmaceuticals VRTX announced positive data from the phase IIb AMPLIFIED study, which evaluated its investigational drug, inaxaplin, for the treatment of patients with APOL1-mediated kidney disease ("AMKD") and modest proteinuria a... Full story

Yahoo Finance • 8 days ago

AstraZeneca's Trixeo Secures Approval for Asthma in the EU

AstraZeneca AZN announced that the European Commission has approved its respiratory drug, Trixeo Aerosphere, for a new indication. The drug is approved in the European Union (EU) as a maintenance treatment for previously treated asthma pa... Full story

Yahoo Finance • 9 days ago

AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis

AbbVie ABBV announced that the European Commission ("EC") has approved its blockbuster immunology drug, Rinvoq (upadacitinib), for a new indication. The drug is approved in the European Union for the treatment of active polyarticular juven... Full story

Yahoo Finance • 9 days ago

Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study

Novo NVO announced top-line results from two phase III studies evaluating once-weekly CagriSema, its investigational fixed-dose combination of cagrilintide and semaglutide, in obesity and type II diabetes (T2D). In the REIMAGINE 5 study, C... Full story

Yahoo Finance • 10 days ago

AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU

AstraZeneca AZN announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of its rare-disease drug, Klygefa (gefurulimab), as an add-on... Full story

Yahoo Finance • 10 days ago

Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU

Novo NVO announced that its once-weekly growth hormone therapy Sogroya (somapacitan) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating children with idiopath... Full story

Yahoo Finance • 13 days ago

Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union

Novo NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of denecimig (Mim8) for the treatment of hemophilia A, with or witho... Full story

Yahoo Finance • 14 days ago

Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery

Novo NVO is expanding its artificial intelligence (AI) capabilities through a new collaboration with Anthropic to accelerate drug discovery and development of new medicines. Under the agreement, Novo will use Anthropic's models and Claude... Full story

Yahoo Finance • 20 days ago

AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study

AbbVie ABBV announced positive top-line data from the phase III LUNA study, which evaluated atogepant, an oral calcitonin gene-related peptide receptor antagonist, for preventive treatment of menstrual migraine in adult women. Menstrual mi... Full story

Yahoo Finance • 21 days ago

Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC

Bayer BAYRY announced that the FDA has granted approval to sevabertinib through an accelerated pathway for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have... Full story

Yahoo Finance • 29 days ago

AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal

AstraZeneca AZN announced positive data from the phase III SANOVO study evaluating Tagrisso (osimertinib) plus Orpathys (savolitinib) in treatment-naïve patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC) w... Full story

Yahoo Finance • last month

BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down

BioNTech BNTX announced that it has discontinued the phase II BNT122-01 study evaluating autogene cevumeran for the treatment of patients with high-risk stage II or stage III colorectal cancer ("CRC") whose tumors had been surgically remov... Full story

Yahoo Finance • last month

LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes

The FDA has approved Eli Lilly's LLY Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type II diabetes (T2D). The new indication includes patients with T2D who are at high risk for major adverse cardiovascular events (M... Full story

Yahoo Finance • last month

AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study

AstraZeneca AZN and its partner Amgen AMGN jointly announced positive top-line data from the late-stage CROSSING study, which evaluated Tezspire (tezepelumab) in adults and adolescents with eosinophilic esophagitis (EoE). The study met all... Full story

Yahoo Finance • last month

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO RGNX stock plunged 24.9% on Monday after the FDA placed a clinical hold on its investigational one-time gene therapy, RGX-121, for the treatment of boys with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome.... Full story

Yahoo Finance • last month

Here's Why You Should Add ACET Stock to Your Portfolio Now

Adicet Bio ACET continues to make steady progress with prula-cel/prulacabtagene leucel (formerly known as ADI-001),the company's lead product candidate and primary clinical value driver in autoimmune diseases. It is a first-in-class invest... Full story

Yahoo Finance • last month

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

Acadia Pharmaceuticals ACAD announced that the European Commission (EC) has granted marketing authorization for Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and old... Full story

Yahoo Finance • last month

Real Parkinson’s Disease Hope from Jupiter Neurosciences

By Mike Sheikh Parkinson's Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate.   The market isn't recognizing the story yet... Full story

Yahoo Finance • 2 months ago

AC Immune First Half 2026 Financial and Corporate Update

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-t... Full story

Yahoo Finance • 5 months ago

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune SA AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026 In... Full story